ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in patients with cardiac failure symptoms and preserved ejection fraction, according to the new study presented on Sunday at ESC 2019 scientific session in Paris and simultaneously published in NEJM.

Despite the negative results, we remain hopeful that this drug could bridge the gap in the treatment of this population on the rise.

After a mean 3 year follow up, primary end point rate every 100 patients/year was 12.8 with valsartan/sacubritil vs. 14.6 for valsartan alone (RR 0.87, CI 95% 0.75 to 1.01). A favorable trend, but with no significance.


Read also: ESC 2019 | THEMIS: Ticagrelor in Diabetics with Stable Coronary Artery Disease.


Secondary end points, of exploratory nature, showed improved functional class and quality of life together with lower chance of kidney function deterioration with the sacubitril/valsartan combination.

At sub-group analysis, it seems to have a special benefit in women. This does not come as a surprise since it is women who most frequently present cardiac failure with preserved function.

This drug combination has been approved for patients with chronic cardiac failure with reduced ejection fraction (40% or lower) based on the PARADIGM-HF outcomes. In this study, the combination sacubritil/valsartan was indeed capable of reducing cardiovascular death rate and rehospitalization for cardiac failure.

Despite the PARAGON-HF outcomes, we should not lose hope on the benefit of these drugs for patients with preserved function, seeing as no drugs have been proved effective in this context.

Original title: Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.

Reference: Solomon SD et al. N Engl J Med. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....